Prescrire Int. 2013 Oct;22(142):249.
Extended follow-up of participants in the "DCCT" trial showed that, in type 1 diabetes, aiming for near-physiological blood glucose concentrations from the start of therapy reduces the risk of diabetic retinopathy, cardiovascular complications and renal impairment.
“糖尿病控制与并发症试验”(DCCT)参与者的长期随访表明,对于1型糖尿病患者,从治疗开始就将血糖浓度控制在接近生理水平可降低糖尿病视网膜病变、心血管并发症和肾功能损害的风险。